Idexx Laboratories has steadily increased its scale and reach in the veterinary diagnostic lab business to dig a narrow moat. It is well-positioned to benefit from two key trends. First, pet ownership ...
Idexx Laboratories (IDXX) reported $1.11 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 10.6%. EPS of $3.63 for the same period compares to $2.44 a year ...
Zacks Investment Research on MSN
Why is Idexx (IDXX) up 0.5% since last earnings report?
It has been about a month since the last earnings report for Idexx Laboratories (IDXX). Shares have added about 0.5% in that time frame, outperforming the S&P 500. But investors have to be wondering, ...
For the quarter ended September 2024, Idexx Laboratories (IDXX) reported revenue of $975.54 million, up 6.6% over the same period last year. EPS came in at $2.80, compared to $2.53 in the year-ago ...
IDEXX Laboratories, Inc. (IDXX)’s share price is up by 2.6% over the past month. Over the past five years, IDEXX has been up 50% in the last five years, which is less than the market return. The last ...
Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results